NCT01020994View on ClinicalTrials.gov

Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Eczema
Interventions
DRUG

LAS41003

Once daily, topically

DRUG

LAS189962

Once daily, topically

DRUG

LAS189961

Once daily, topically

Trial Locations (1)

Unknown

Investigational Site, Bochum

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY

NCT01020994 - Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema | Biotech Hunter | Biotech Hunter